402 related articles for article (PubMed ID: 22499677)
1. α-Synuclein phosphorylation as a therapeutic target in Parkinson's disease.
Braithwaite SP; Stock JB; Mouradian MM
Rev Neurosci; 2012 Mar; 23(2):191-8. PubMed ID: 22499677
[TBL] [Abstract][Full Text] [Related]
2. S-Nitrosylation of G protein-coupled receptor kinase 6 and Casein kinase 2 alpha modulates their kinase activity toward alpha-synuclein phosphorylation in an animal model of Parkinson's disease.
Wu W; Sung CC; Yu P; Li J; Chung KKK
PLoS One; 2020; 15(4):e0232019. PubMed ID: 32343709
[TBL] [Abstract][Full Text] [Related]
3. In vivo modulation of polo-like kinases supports a key role for PLK2 in Ser129 α-synuclein phosphorylation in mouse brain.
Bergeron M; Motter R; Tanaka P; Fauss D; Babcock M; Chiou SS; Nelson S; San Pablo F; Anderson JP
Neuroscience; 2014 Jan; 256():72-82. PubMed ID: 24128992
[TBL] [Abstract][Full Text] [Related]
4. Targeting phosphatases as the next generation of disease modifying therapeutics for Parkinson's disease.
Braithwaite SP; Voronkov M; Stock JB; Mouradian MM
Neurochem Int; 2012 Nov; 61(6):899-906. PubMed ID: 22342821
[TBL] [Abstract][Full Text] [Related]
5. Models of α-synuclein aggregation in Parkinson's disease.
Giráldez-Pérez R; Antolín-Vallespín M; Muñoz M; Sánchez-Capelo A
Acta Neuropathol Commun; 2014 Dec; 2():176. PubMed ID: 25497491
[TBL] [Abstract][Full Text] [Related]
6. Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies.
Oueslati A; Fournier M; Lashuel HA
Prog Brain Res; 2010; 183():115-45. PubMed ID: 20696318
[TBL] [Abstract][Full Text] [Related]
7. Specificity and regulation of casein kinase-mediated phosphorylation of alpha-synuclein.
Waxman EA; Giasson BI
J Neuropathol Exp Neurol; 2008 May; 67(5):402-16. PubMed ID: 18451726
[TBL] [Abstract][Full Text] [Related]
8. Implication of Alpha-Synuclein Phosphorylation at S129 in Synucleinopathies: What Have We Learned in the Last Decade?
Oueslati A
J Parkinsons Dis; 2016; 6(1):39-51. PubMed ID: 27003784
[TBL] [Abstract][Full Text] [Related]
9. The contribution of alpha synuclein to neuronal survival and function - Implications for Parkinson's disease.
Benskey MJ; Perez RG; Manfredsson FP
J Neurochem; 2016 May; 137(3):331-59. PubMed ID: 26852372
[TBL] [Abstract][Full Text] [Related]
10. Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions.
Paleologou KE; Oueslati A; Shakked G; Rospigliosi CC; Kim HY; Lamberto GR; Fernandez CO; Schmid A; Chegini F; Gai WP; Chiappe D; Moniatte M; Schneider BL; Aebischer P; Eliezer D; Zweckstetter M; Masliah E; Lashuel HA
J Neurosci; 2010 Mar; 30(9):3184-98. PubMed ID: 20203178
[TBL] [Abstract][Full Text] [Related]
11. Effects of Serine 129 Phosphorylation on α-Synuclein Aggregation, Membrane Association, and Internalization.
Samuel F; Flavin WP; Iqbal S; Pacelli C; Sri Renganathan SD; Trudeau LE; Campbell EM; Fraser PE; Tandon A
J Biol Chem; 2016 Feb; 291(9):4374-85. PubMed ID: 26719332
[TBL] [Abstract][Full Text] [Related]
12. Contribution of endogenous G-protein-coupled receptor kinases to Ser129 phosphorylation of alpha-synuclein in HEK293 cells.
Sakamoto M; Arawaka S; Hara S; Sato H; Cui C; Machiya Y; Koyama S; Wada M; Kawanami T; Kurita K; Kato T
Biochem Biophys Res Commun; 2009 Jul; 384(3):378-82. PubMed ID: 19410557
[TBL] [Abstract][Full Text] [Related]
13. The role of Ser129 phosphorylation of α-synuclein in neurodegeneration of Parkinson's disease: a review of in vivo models.
Sato H; Kato T; Arawaka S
Rev Neurosci; 2013; 24(2):115-23. PubMed ID: 23314528
[TBL] [Abstract][Full Text] [Related]
14. The role of posttranslational modifications of α-synuclein and LRRK2 in Parkinson's disease: Potential contributions of environmental factors.
Pajarillo E; Rizor A; Lee J; Aschner M; Lee E
Biochim Biophys Acta Mol Basis Dis; 2019 Aug; 1865(8):1992-2000. PubMed ID: 30481588
[TBL] [Abstract][Full Text] [Related]
15. Fasudil attenuates aggregation of α-synuclein in models of Parkinson's disease.
Tatenhorst L; Eckermann K; Dambeck V; Fonseca-Ornelas L; Walle H; Lopes da Fonseca T; Koch JC; Becker S; Tönges L; Bähr M; Outeiro TF; Zweckstetter M; Lingor P
Acta Neuropathol Commun; 2016 Apr; 4():39. PubMed ID: 27101974
[TBL] [Abstract][Full Text] [Related]
16. SMG1 identified as a regulator of Parkinson's disease-associated alpha-synuclein through siRNA screening.
Henderson-Smith A; Chow D; Meechoovet B; Aziz M; Jacobson SA; Shill HA; Sabbagh MN; Caviness JN; Adler CH; Driver-Dunckley ED; Beach TG; Yin H; Dunckley T
PLoS One; 2013; 8(10):e77711. PubMed ID: 24204929
[TBL] [Abstract][Full Text] [Related]
17. Kinases as targets for Parkinson's disease: from genetics to therapy.
Vancraenenbroeck R; Lobbestael E; Maeyer MD; Baekelandt V; Taymans JM
CNS Neurol Disord Drug Targets; 2011 Sep; 10(6):724-40. PubMed ID: 21838679
[TBL] [Abstract][Full Text] [Related]
18. Serine 129 phosphorylation of membrane-associated α-synuclein modulates dopamine transporter function in a G protein-coupled receptor kinase-dependent manner.
Hara S; Arawaka S; Sato H; Machiya Y; Cui C; Sasaki A; Koyama S; Kato T
Mol Biol Cell; 2013 Jun; 24(11):1649-60, S1-3. PubMed ID: 23576548
[TBL] [Abstract][Full Text] [Related]
19. Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications.
Qing H; Wong W; McGeer EG; McGeer PL
Biochem Biophys Res Commun; 2009 Sep; 387(1):149-52. PubMed ID: 19576176
[TBL] [Abstract][Full Text] [Related]
20. Increased 14-3-3 phosphorylation observed in Parkinson's disease reduces neuroprotective potential of 14-3-3 proteins.
Slone SR; Lavalley N; McFerrin M; Wang B; Yacoubian TA
Neurobiol Dis; 2015 Jul; 79():1-13. PubMed ID: 25862939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
